It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

Latest Publications:

As of 6-April-2020, a total of 28921 patients received siponimod in clinical trials including the ongoing open-label extension, and an estimated 5000 patients in the postmarketing experience* as of 25-September-20202

clinical-trial-and-postmarketing-data
*Postmarketing experience is estimated based on the sales data in different countries where siponimod is approved
Siponimod US Prescribing Information
Click here to request siponimod local RMP educational material

Report an adverse event

Border image
Abbreviations
COVID-19, corona virus disease-19; PML, progressive multifocal leukoencephalopathy
References
1. Data on File, cutoff date 6-Apr-2020, Novartis Pharma AG.
2. Data on File, PSUR 2, cutoff date 25-Sep-2020, Novartis Pharma AG.

The Pregnancy outcome Intensive Monitoring (PRIM) program is based on enhanced pharmacovigilance of the Novartis spontaneous reporting system. PRIM is an adverse event outcomes intensive monitoring program to collect information (targeted follow-up checklists) about pregnancy in patients exposed to siponimod immediately before or during pregnancy and infant outcomes 12 months after delivery.